What's Happening?
The University of Memphis School of Public Health has been awarded a four-year, $1.24 million grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
This funding will support the development and testing of an AI-powered wearable device designed to provide early warnings for Chronic Obstructive Pulmonary Disease (COPD) flare-ups. Dr. Maryam Karimi, Director of Research and Associate Professor at the School of Public Health and founder of CanAiry, LLC, is leading the project. The device, called the CanAiry Wearable Sensing Unit, is miniaturized and low-power, continuously tracking a patient's breathing and surrounding air quality. These readings will be combined with satellite and ground-based air quality data, with AI models predicting rising risk and sending alerts to patients and physicians. The technology has undergone initial testing with support from the National Science Foundation and an NIH Small Business Technology Transfer award. The new grant will fund an expanded study involving 100 COPD patients in Memphis, with Memphis Lung Physicians, led by Dr. Jeffrey G. Wright, serving as the clinical partner.
Why It's Important?
This grant is significant because it addresses a critical need in managing COPD, a disease affecting approximately 16 million Americans and ranking as the fourth leading cause of death in the U.S., costing an estimated $50 billion annually. Current methods often only alert patients to trouble when they experience severe breathing difficulties, leading to frequent hospital and emergency room visits, particularly in areas like Memphis and Shelby County. The AI-powered wearable aims to provide warnings hours or days in advance, allowing for timely interventions that could prevent hospitalizations and improve patients' quality of life. This early detection system could reduce healthcare burdens and costs associated with emergency care for COPD exacerbations. The project also emphasizes reaching underserved communities, which are disproportionately affected by air pollution, heat, and limited access to care, making the technology's impact potentially far-reaching in addressing health disparities.
What's Next?
The next phase involves an expanded study with 100 COPD patients in Memphis, where the smaller, next-generation device will be tested in real clinical settings. The research team, a collaboration of public health, engineering, computer science, and frontline medicine experts, will work with Memphis Lung Physicians to recruit patients and integrate the device into daily care. Following successful testing in Memphis, the platform is designed for broader expansion. The team plans to adapt the technology for other lung conditions, such as asthma, and deploy it in communities across the country, especially those currently underserved by existing medical tools. The ultimate goal is to bring this device to market, providing a practical and effective tool for both patients and doctors to manage COPD proactively and prevent medical emergencies.
Beyond the Headlines
This initiative represents a broader trend in healthcare towards personalized, predictive medicine, leveraging wearable technology and artificial intelligence to manage chronic conditions. The integration of environmental data, such as air quality, with individual physiological data highlights a holistic approach to health that considers external factors influencing disease progression. This project could set a precedent for how other chronic respiratory illnesses are managed, potentially leading to similar AI-driven early warning systems. Furthermore, the focus on making this technology accessible to under-resourced neighborhoods underscores an ethical commitment to health equity, aiming to bridge gaps in healthcare access and outcomes. The success of this device could also spur further innovation in miniaturized, low-power medical devices, transforming how patients monitor their health outside traditional clinical settings.








